Article No
AG-20T-0308R-C100
anti-TLR9, mAb (ABM1C51) (R-PE)
anti-TLR9, mAb (ABM1C51) (R-PE)
Antibodies Primary
Specifications
| Application | FC |
| Article No | AG-20T-0308R-C100 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT |
| Clone | ABM1C51 |
| Clone Type | monoclonal |
| Concentration | 0.2 mg/ml |
| Conjugation | PE |
| Description | anti-TLR9, mAb (ABM1C51) (R-PE) |
| Supplier | Adipogen Life Sciences |
| Format | Liquid |
| Immunogen | Recombinant human TLR9 protein (aa 100-290). |
| Isotype | IgG1 k |
| Notes | Monoclonal Antibody. Recognizes human and mouse TLR9. Isotype: Mouse IgG1kappa. Clone: ABM1C51. Applications: FACS. Liquid. In PBS containing 0.05% sodium azide. TLR9 (Toll-like Receptor 9) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 is expressed by numerous cells of the immune system such as B lymphocytes, monocytes, natural killer (NK) cells and plasmacytoid dendritic cells. It is expressed intracellularly, within the endosomal compartments and functions to alert the immune system of viral and bacterial infections by binding to DNA rich in CpG motifs. This nucleotide-sensing TLR is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (also called oligodinucleotides, ODNs), and consequently signals via MYD88 and TRAF6, leading to NF-kappaB activation, cytokine secretion and the inflammatory response and eventually activation of a Th1-biased adaptive immune attack. Specific TLR9 agonists have been shown to have substantial antitumor activity, making the TLR9 signaling pathway an interesting target for therapeutic research.|TLR9 (Toll-like Receptor 9) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 is expressed by numerous cells of the immune system such as B lymphocytes, monocytes, natural killer (NK) cells and plasmacytoid dendritic cells. It is expressed intracellularly, within the endosomal compartments and functions to alert the immune system of viral and bacterial infections by binding to DNA rich in CpG motifs. This nucleotide-sensing TLR is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (also called oligodinucleotides, ODNs), and consequently signals via MYD88 and TRAF6, leading to NF-kappaB activation, cytokine secretion and the inflammatory response and eventually activation of a Th1-biased adaptive immune attack. Specific TLR9 agonists have been shown to have substantial antitumor activity, making the TLR9 signaling pathway an interesting target for therapeutic research. |
| Alias Names | Toll-like Receptor 9; CD289 |
| Product Type | Antibodies Primary |
| Purity | Protein G purified. |
| Research area | Immunology |
| Shipping Information | BLUE ICE |
| Size | 100 ug |
| Source / Host | mouse |
| Species Reactivity | human, mouse |
| Stability | Stable for at least 6 months after receipt when stored at +4°C. |
| Storage | 4°C |
| Substrate / Buffer | Liquid. In PBS containing 0.05% sodium azide. |
| Technical Specifications | Monoclonal Antibody. Recognizes human and mouse TLR9. Isotype: Mouse IgG1kappa. Clone: ABM1C51. Applications: FACS. Liquid. In PBS containing 0.05% sodium azide. TLR9 (Toll-like Receptor 9) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 is expressed by numerous cells of the immune system such as B lymphocytes, monocytes, natural killer (NK) cells and plasmacytoid dendritic cells. It is expressed intracellularly, within the endosomal compartments and functions to alert the immune system of viral and bacterial infections by binding to DNA rich in CpG motifs. This nucleotide-sensing TLR is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (also called oligodinucleotides, ODNs), and consequently signals via MYD88 and TRAF6, leading to NF-kappaB activation, cytokine secretion and the inflammatory response and eventually activation of a Th1-biased adaptive immune attack. Specific TLR9 agonists have been shown to have substantial antitumor activity, making the TLR9 signaling pathway an interesting target for therapeutic research. |
| Product Page Updated | 2024-02-01T08:25:01.492Z |
